Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
December 20 2019 - 9:00AM
MannKind Corporation (NASDAQ:
MNKD) announced today that Hypoglycemia is reduced
with use of inhaled Technosphere® Insulin relative to insulin
aspart in type 1 diabetes mellitus has been published online in
DIABETICMedicine.
This post-hoc analysis was designed to further
evaluate the risk of hypoglycemia observed in adults with type 1
diabetes who were treated with inhaled Technosphere Insulin
(Afrezza®) or subcutaneous insulin aspart. Specifically, the
research controlled for the level of any HbA1c achieved on the
incidence rates of hypoglycemia (low levels of sugar in the blood)
in 375 adults with type 1 diabetes. The data demonstrated the
following:
- Participants treated with Afrezza experienced statistically
significantly lower rates of level 1 (blood glucose ≤ 3.9 mmol/L or
70 mg/dL) and level 2 (blood glucose ≤ 3.0 mmol/L or 54 mg/dL)
hypoglycemic events. There was also a trend towards lower rates of
level 3 hypoglycemia (requiring external assistance for recovery)
than participants treated with insulin aspart.
- The lower rate of hypoglycemia with Afrezza was observed across
the range of end-of-treatment A1c levels.
- Due to its unique pharmacokinetic/pharmacodynamic profile,
Afrezza was associated with higher rates of hypoglycemia 30–60
minutes after meals but significantly lower rates 2–6 hours after
meals.
These data indicate that participants using
Afrezza experienced clinically non-inferior glycemic control and
lower hypoglycemia rates across a range of A1c levels compared with
participants receiving insulin aspart.
Hypoglycemia and fear of hypoglycemia are
barriers to effective insulin therapy and may prevent people with
diabetes from achieving glycemic targets. Potential risks
associated with hypoglycemia include, but are not limited to,
treatment costs, limiting the individual patient’s capacity to
intensify diabetes control, individual patient rates of
productivity, as well as many other debilitating effects.
The published research can be found online
at https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14202
About Afrezza®
Available by prescription, Afrezza® (insulin
human) Inhalation Powder is a rapid-acting inhaled insulin
indicated to improve glycemic control in adult patients with
diabetes mellitus. Afrezza consists of a dry powder formulation of
human insulin delivered from a small and portable inhaler.
Administered at the beginning of a meal, Afrezza dissolves rapidly
upon inhalation to the lung and passes quickly into the bloodstream
(in less than one minute). This rapid absorption allows Afrezza to
begin reducing blood sugar levels within minutes of administration.
Afrezza is available in 4-unit, 8-unit and 12-unit single-dose
cartridges of insulin powder that can be used, as prescribed by a
health care professional, in combination with other diabetes
medications to achieve target blood sugar levels. For Afrezza doses
exceeding 12 units, patients may use a combination of existing
cartridge strengths. For more information about Afrezza, please
visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only orally
inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
MannKind Contact: 818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024